AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Phase 2
Active, not recruiting
- Conditions
- Mantle Cell Lymphoma (MCL)
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 108
- Registration Number
- NCT05951959
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3
Recruiting
- Conditions
- Breast Cancer, Early Breast Cancer
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5500
- Registration Number
- NCT05952557
- Locations
- 🇬🇧
Research Site, Whitchurch, United Kingdom
Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
Completed
- Conditions
- Muscle-invasive Bladder CancerNon Muscle Invasive Bladder CancerUrothelial Carcinoma
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT05945108
- Locations
- 🇧🇷
Research Site, Sao Paulo, Brazil
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
Phase 3
Active, not recruiting
- Conditions
- Non-Muscle- Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT05943106
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
Phase 2
Active, not recruiting
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT05941897
- Locations
- 🇷🇺
Research Site, St. Petersburg, Russian Federation
A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA
Active, not recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 625
- Registration Number
- NCT05939128
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
Phase 1
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT05938270
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
Benralizumab Patient Access Programme Study: Retrospective Study in UK Severe Asthma Centres
Completed
- Conditions
- Asthma
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 276
- Registration Number
- NCT05932849
- Locations
- 🇬🇧
Addenbrookes Hospital, Cambridge, United Kingdom
🇬🇧St Bartholomew's Hospital, London, United Kingdom
🇬🇧St James's University Hospital, Leeds, United Kingdom
Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants
Phase 1
Completed
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- Biological: Placebo (Cohort 3)Biological: Placebo (Cohort 2)Biological: AZD3152 (Cohort 3)Biological: AZD3152 (Cohort 2)Biological: AZD3152 (Cohort 1)Biological: Placebo (Cohort 1)
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT05932641
- Locations
- 🇯🇵
Research Site, Fukuoka-shi, Japan
OPTIMISE-CKD Drug Utilization
Completed
- Conditions
- Chronic Kidney Disease
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2682052
- Registration Number
- NCT05932901
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
© Copyright 2025. All Rights Reserved by MedPath